Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.

CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu. Get Real-Time News ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer, BioNTech win bid to invalidate CureVac's UK COVID ...

CureVac (NASDAQ:CVAC – Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 3,940,000 shares ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will "vigorously" defend itself. CureVac revealed yesterday that ...

Overview: CureVac N.V. is a biopharmaceutical company specializing in the development of transformative mRNA-based medicines, with a market cap of approximately $684.16 million. Operations ...

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation ...

Shares in vaccine developers jumped on Tuesday after the US reported its first human death from the H5 strain of bird flu.

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...